0900-0915

Opening and Welcome. Chair: Prof Pavlidis

0900-0905

Welcome from CUP Foundation

0905-0915

Objectives of the Meeting and scientific introduction

N. Pavlidis

0915-1100

Module 1 – Epidemiology, Biology, Pathology. Chair: Dr Wasan

0915-0945

Epidemiology

 K. Hemminki

0945-10:15

Biology

G. Pentheroudakis

1015-1045

Pathology

 K. Oien

1045-1100

Discussion

1100-1130

Break

1130-1315

Module 2 -  Diagnostic challenges, subsets, prognosis. Chair: Dr Wasan

1130-1200

The role of imaging

B. Taylor 

1200-1230

The role of molecular profiling and new diagnostic technologies

R. Wassman

1230-1300

Natural history, clinicopathological subsets,and prognostic factors  

N. Pavlidis  

1300-1315

Discussion

1315-1415

Lunch

1415-1600

Module 3 – Treating CUP. Chair: Dr Osborne

1415-1445

Treating favourable prognosis subsets   

N. Pavlidis  

1445-1515

Treating CUP subsets by empirical or by molecular-assay directed treatment   

G. Pentheroudakis

1515-1545

Ongoing clinical trials: CUP-One (UK) and SUPER - Solving Unknown Primary cancER - Australia)

H. Wasan

P. Schofield

1545-1600

Discussion

1600-1630

Break

1630-1730

S. Lowndes, N. Pavlidis, H. Wasan, R. Osborne

Dinner (Own arrangements)

0830-1015

Module 4  – Guidelines, psychosocial aspects, palliative care. Chair: Dr Osborne

0830-0915

Existing CUP Guidelines (NICE, NCCN, ESMO);  Criticism and perspectives

R. Osborne

G. Pentheroudakis

0915-1000

Psychosocial aspects facing CUP patients; supportive and palliative care

C. Davis

P. Schofield

1000-1030

Discussion (Including Jon Lacey, patient/ carer rep.)

1030-1045

Break

1045-1200

Module 5 – Future perspectives. Chair: Prof Pavlidis

1045-1115

Defining Actionable Molecular Phenotypes for Therapy using next generation sequencing

A. Biankin 

1115-1130

Personalising cancer medicine – from CUP to site specific cancers and back again

H. Wasan 

1130-1145

Discussion

1145 - 1200

Closing remarks and take home messages

N. Pavlidis